Mesoblast completed enrollment of 350 patients in a Phase 3 trial testing rexlemestrocel-L, a mesenchymal stromal cell therapy, for chronic low back pain from degenerative disc disease. The trial measures whether a single intra-discal injection produces durable pain reduction at 12 months, with secondary outcomes including functional improvement and opioid cessation.
Key Points
- Phase 3 trial enrolled 350 patients with degenerative disc disease-related chronic low back pain
- Single intra-discal injection of rexlemestrocel-L tested for 12-month durable pain reduction
- Secondary endpoints include functional recovery and reduction in opioid medication use
Longevity Analysis
Mesenchymal stromal cell therapy targets tissue regeneration within the intervertebral disc, addressing a structural defect that initiates inflammatory cascades affecting pain signaling, movement capacity, and systemic stress response. Chronic low back pain typically drives compensatory neural patterning, altered movement mechanics, and prolonged elevation of stress hormones — all of which accelerate age-related decline across multiple systems. If durable pain reduction is achieved through a single injection, this approach would shift the treatment paradigm from symptom suppression to structural restoration, potentially interrupting the degenerative feedback loop that perpetuates disability and secondary health decline in aging populations.
Original published by LT Wire.